Rallybio’s Promising Developments and Financial Stability Justify Buy Rating

H.C. Wainwright analyst Mitchell Kapoor has reiterated their bullish stance on RLYB stock, giving a Buy rating on March 14.

Mitchell Kapoor has given his Buy rating due to a combination of factors related to Rallybio’s ongoing developments and financial outlook. The initiation of the FNAIT study, with the first pregnant mother dosed, marks a significant milestone for Rallybio. This study targets a rare immune disorder, and the successful dosing suggests potential for RLYB212 to become a standard-of-care treatment, given the absence of FDA-approved therapies for FNAIT.
Additionally, several key catalysts are anticipated in 2025, including data presentations and study initiations for Rallybio’s pipeline products such as RLYB212, RLYB116, and REV102. Financially, Rallybio reported a smaller net loss than expected for 4Q24, and with a cash reserve of $65.5 million, the company is well-positioned to fund its operations into the second half of 2026. These factors collectively support the Buy rating and a 12-month price target of $5.

Kapoor covers the Healthcare sector, focusing on stocks such as Halozyme, Sarepta Therapeutics, and Summit Therapeutics. According to TipRanks, Kapoor has an average return of -19.9% and a 28.76% success rate on recommended stocks.